Klinik Ottakring, 2.Medizinische Abteilung mit Pneumologie, Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
Ansprechpartner: OA Dr. Klaus Kirchbacher klaus.kirchbacher@gesundheitsverbund.at
Landsteiner Lung Cancer Research Platform (LALUCA) – A prospective analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Patientenpopulation: alle Patientinnen und Patientin mit Lungenkrebs
Zeitrahmen: seit 2020, open end
Universitätsklinikum Krems, Abteilung für Pneumologie
NSCLC early stage
SKYSCRAPER 03: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Start: Mai 2021
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at
1st line ES-SCLC
SPACE: Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide
Start: Okt. 2020
Ansprechpartner: OA Dr. Klaus Hackner, klaus.hackner@krems.lknoe.at
SCLC relapsed, refractory
AMG 757 (DeLphi-301): A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Start: Feb. 2022
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at
Kepler Universitätsklinikum, Universitätsklinik für Innere Medizin 4 – Pneumologie
Ansprechpartnerin: OÄ Dr. Romana Wass, PhD romana.wass@kepleruniklinikum.at
NSCLC early stage
KEYNOTE-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03924869
SKYSCRAPER 03: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
https://clinicaltrials.gov/ct2/show/NCT04513925
1st line ES-SCLC
Klinikum Klagenfurt, Abteilung für Lungenkrankheiten
Ansprechpartner: Prim. Dr. Markus Rauter, Markus.Rauter@kabeg.at
NSCLC early stage
Canopy A: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and
safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
NSCLC metastatic
NIVO PASS: Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
ImReal MO40653: A non-interventional, multi-centre, multiple cohort study to investigate the outcomes and safety of atezolizumab under real-life conditions in patients treated in routine clinical practice.
ALK positive
Brigatinib 5007 – PASS: A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-
MO42122 ReAlec: A multicenter noninterventional cohort study to evaluate the real world clinical managements and outcomes of patients diagnosed with ALK positive advanced NSCLC treated with Alectinib (Realec)
1st line ES-SCLC
AIO-TRK-0119-SPACE: Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide (SPACE)
Medizinische Universität Graz, Klinische Abteilung für Onkologie, in Zusammenarbeit mit LKH Hochsteiermark
Ansprechpartnerin: Priv.-Doz. Dr. Angelika Terbuch, angelika.terbuch@medunigraz.at
SCLC
Innsbruck Thoracic Oncology Group
Ansprechpartner: Priv.-Doz. Dr. Andreas Pircher, andreas.pircher@i-med.ac.at
NSCLC early stage
INN-WOP1, Phase II: Neoadjuvante Window-Of-Opportunity-Studie zur Kurzzeittherapie mit Pembrolizumab/Lenvatinib vor OP eines NSCLC in frühen Stadien. Postoperativ Pembrolizumab für 1 Jahr. Akademische, monozentrische Studie. Nach erfolgtem Amendment können Patient*innen sowohl vor als auch nach erfolgter histologischer Diagnosesicherung eingeschlossen werden.
Keynote 867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03924869
NSCLC metastatic
Keyvibe, Phase III: Metast. NSCLC, First-Line-Therapie; Randomisierung zwischen CTX + Pembrolizumab vs. CTX + Pembrolizumab + Vibostolimab (Anti-TIGIT-Antikörper)
HER2 Exon 19 or 20 Mutation
Destiny Lung 04: First Line Therapie mestast. NSCLC, Her2-mutiert. Randomisierung zwischen CTX+ Immuntherapie vs. Trastuzumab-Deruxtecan